The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 119 participants.
Also called NCT03819790
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 119 participants
- Registry
-
NCT03819790
-
- Other papers using this trial's data
- Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT03819790. Randomized; no masking; primary purpose treatment. Start 2018-10-02 (actual); primary completion 2019-11-19 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians
- Acronym
- VARIATION 2 SA
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Basal insulin glargine and lixisenatide
- Intervention (Drug)
- Basal insulin Basaglar/Lantus + gliclazide MR
- Intervention (Drug)
- Metformin
- Lead sponsor
- LMC Diabetes & Endocrinology Ltd.
Record details
- Record id
cardio:ct-nct03819790- Content hash
ef7b348c39601729dc23ee1d79494c2cd92a863dd20ddd9460390cb3332dae3d